News

Grants Given to 8 ‘Blue Sky’ Research Projects at Emory, Georgia Tech

Eight grants worth a total of $575,000 were awarded by the McCamish Parkinson’s Disease Innovation Program to research teams at Georgia Tech and Emory University advancing projects into Parkinson’s disease. “These grants are specifically focused on technology-driven research for understanding, treating, and curing Parkinson’s disease,” Garrett Stanley, PhD, professor…

Dosing Completed in Phase 2a Trial of ANVS401

Patient dosing has been completed in the Phase 2a clinical trial testing ANVS401, Annovis Bio’s investigational therapy for Alzheimer’s disease and Parkinson’s disease. An additional 40 patients with Parkinson’s disease were treated with ANVS401, with the company now preparing to share final safety and efficacy data later this year. According to…

Low-frequency DBS May Help Parkinson’s Patients With Walking

Low-frequency deep brain stimulation (DBS) may help to ease balance problems due to postural instability in people with Parkinson’s disease, a small clinical trial reported. But patients with significant tremor prior to starting DBS may not find the treatment tolerable, because it can lead to the re-emergence of…

Study Examines Genetics of Parkinson’s in Latinos

Genetic variations in the gene SNCA are tied to an increased risk of Parkinson’s disease (PD) among Latinos, according to a recent analysis. Also, Latinos with African ancestry are less likely to develop Parkinson’s. The analysis is “the most comprehensive examination of PD genetics in this population [Latinos] to…

Way of Protecting Key Neurons in LRRK2-linked Parkinson’s Seen

In mice with a harmful mutation in the leucine-rich repeat protein kinase 2 (LRRK2) gene, one of the most common genetic causes of Parkinson’s disease, treatment with a small molecule compound restored the recycling of damaged mitochondria — the cells’ powerhouses — from dopamine-producing nerve cells. A failure…

AbbVie Chooses Two Parkinson’s Therapies to Develop With Mission

AbbVie has selected two drug candidates — both targeting enzymes known as DUBs — for further development as possible Parkinson’s disease treatments, as part of the company’s ongoing collaboration with Mission Therapeutics. “We are delighted to have reached this next major milestone in our collaboration with AbbVie and…

MJFF Fellow Working to Raise Black, Minority Presence in Research

A Michael J. Fox Foundation (MJFF) research fellow is leading a study into the role of social determinants in medical mistrust and the lack of clinical trial participation by people with diseases such as Parkinson’s who belong to racial, ethnic and social minority groups. Paris Adkins-Jackson’s study, titled “…